 REDWOOD CITY, Calif., Oct. 28, 2020 GLOBE NEWSWIRE -- Allakos Inc. the Company Nasdaq: ALLK, a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering. The size of the offering is 250 million of shares of its common stock. The Company is offering 3,048,781 shares at a public offering price of 82.00 per share. The offering is expected to close on November 2, 2020, subject to the satisfaction of customary closing conditions. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to 457,317 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. 